Aurinia Pharmaceuticals Inc (AUPH) vs Novavax, Inc. (NVAX)
- Aurinia Pharmaceuticals Inc AUPH 16.51 −1.32%
- Novavax, Inc. NVAX 11.26 −12.17%
Aurinia Pharmaceuticals Inc and Novavax, Inc. are both Biotechnology companies. Aurinia Pharmaceuticals Inc and Novavax, Inc. are of similar size ($2.2B and $2.1B). Novavax, Inc. has negative trailing earnings, so its P/E is not meaningful; Aurinia Pharmaceuticals Inc trades at 6.9×. Aurinia Pharmaceuticals Inc grew revenue faster over the last twelve months: 19.8% against −61.6%. Aurinia Pharmaceuticals Inc has the higher net margin (100.8% vs −59.9%) and the higher return on invested capital (40.8% vs 0.00%). Across the 17 metrics below, Aurinia Pharmaceuticals Inc leads on 13 and Novavax, Inc. on 4.
Valuation
Profitability
| Metric | AUPH | NVAX | Biotechnology median |
|---|---|---|---|
| Gross margin | 90.36% | 78.60% | 65.16% |
| Operating margin | 45.15% | (56.58%) | 0.00% |
| Net margin | 100.84% | (59.87%) | 0.00% |
| Free cash flow margin | 56.20% | (10.20%) | 0.00% |
| Return on equity | 66.12% | 323.66% | (56.36%) |
| Return on assets | 48.52% | (21.62%) | (48.04%) |
| Return on invested capital | 40.76% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack